title: Evaluation of efficacy of bruceine A, a natural quassinoid compound extracted from a medicinal plant, Brucea javanica, for canine babesiosis.
abstract: Bruceine A, a natural quassinoid compound extracted from the dried fruits of Brucea javanica (L.) Merr., was evaluated for its antibabesial activity in vitro and in vivo. Bruceine A inhibited the in vitro growth of Babesia gibsoni in canine erythrocytes at lower concentration compared with the standard antibabesial drug diminazene aceturate and killed the parasites within 24 hr at a concentration of 25 nM. Oral administration of bruceine A at a dosage of 6.4 mg/kg/day for 5 days resulted in no clinical findings in a dog with normal ranges of hematological and biochemical values in the blood. Three dogs were infected with B. gibsoni and two of them were treated with bruceine A at a dosage of 6.4 mg/kg/day for 6 days from day 5 post-infection. An untreated dog developed typical acute babesiosis symptoms including severe anemia, high fever, and complete loss of appetite and movement. However, the two bruceine A-treated dogs maintained their healthy conditions throughout the experimental period of 4 weeks although complete elimination of parasites from the peripheral blood was not achieved and decreases in the packed cell volume and the erythrocyte and platelet counts were observed. Since natural quassinoid compounds have been used as traditional medicines for the treatment of various ailments including cancer and malaria, the present results suggest that bruceine A or other related compounds are potential candidates for the treatment of canine babesiosis.
authors.affiliation: Laboratory of Parasitology, Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 8, Sapporo, Japan.
authors.forename: Ryo
authors.initials: R
authors.lastname: Nakao
authors.forename: Chiaki
authors.initials: C
authors.lastname: Mizukami
authors.forename: Yuta
authors.initials: Y
authors.lastname: Kawamura
authors.lastname: Subeki
authors.forename: Saw
authors.initials: S
authors.lastname: Bawm
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yamasaki
authors.forename: Yoshimitsu
authors.initials: Y
authors.lastname: Maede
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Matsuura
authors.forename: Kensuke
authors.initials: K
authors.lastname: Nabeta
authors.forename: Nariaki
authors.initials: N
authors.lastname: Nonaka
authors.forename: Yuzaburo
authors.initials: Y
authors.lastname: Oku
authors.forename: Ken
authors.initials: K
authors.lastname: Katakura
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001403:Babesia / Q000187:drug effects* / Q000235:genetics; D001404:Babesiosis / Q000188:drug therapy / Q000662:veterinary*; D032269:Brucea / Q000737:chemistry*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D007700:Kinetics; D018512:Parasitemia / Q000662:veterinary; D016133:Polymerase Chain Reaction / Q000662:veterinary; D036702:Quassins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D036702:Quassins; C024964:bruceine A